Novo Nordisk launches its shortest needle: NovoFine® Plus, compatible with all major pen devices
Bagsværd, Denmark, 20 January 2014: Novo Nordisk is now launching NovoFine® Plus, 32G 4 mm an ultra-thin, ultra-short universal pen needle that aims to make injections more comfortable for patients with diabetes. Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015.
NovoFine® Plus is as thin as two human hairs (1) and 4 mm long (2), making it the shortest needle Novo Nordisk has ever made. Its thinness and length are associated with less pain (3) and less risk of intramuscular injection (4).
Studies have shown that people with type 2 diabetes are often reluctant about initiating insulin therapy, with needle anxiety cited as a common barrier to initiation (5). Therefore, good design and user-friendly features that take into account patient concerns, such as ease of use and comfort, are important (5-7).
As NovoFine® Plus uses SuperFlow™ technology, it also offers patients faster injections that need less force (8). It is compatible with major pen devices (9) and has been designed to reduce the risk of bending or breakage (9).
“We know needle anxiety can be a real barrier when people with diabetes start insulin therapy, and in some people this fear really compromises their treatment. Novo Nordisk is committed to improving diabetes care and as part of our broad portfolio within treatment, devices and needles, we’re pleased to provide this new option to people with diabetes,” says Jesper Kløve, senior vice president, Device R&D, Novo Nordisk.
Features of NovoFine® Plus:
• NovoFine® Plus reduces the risk of intramuscular injections because it is only 4 mm long (2); as a comparison, the thickness of the skin varies between 1.9 mm and 2.4 mm around the body (10,11) (even in people with a high BMI). This means that a 4 mm needle can be used for injection with minimal risk of intramuscular injection.
• The short length of NovoFine® Plus means it can be inserted into the skin at a 90º angle without the need to create a ‘skin fold’ before injecting and the flat hub of the needle is designed to make injections more comfortable (12).
• NovoFine® Plus uses SuperFlow™ technology, which increases the width of the internal bore without increasing the outer diameter of the needle. This increases the flow rate and reduces the resistance and force needed to deliver the treatment dose through the needle (9,13), which can be important factors for patients with limited manual dexterity or reduced hand strength, such as children or the elderly.
• NovoFine® Plus has a triple bevel design that may reduce the penetration force required to puncture the skin(14).
Novo Nordisk launched the world’s first pen needle for insulin in 1985; since then the company has striven to improve the injection experience for patients by developing smaller and thinner needles. Novo Nordisk uses advanced technology and design to offer pen needles that provide a more comfortable, convenient and simple injection experience.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.co.uk.
Katrine Sperling +45 4442 6718 firstname.lastname@example.org
Ken Inchausti (US) +1 609 514 8316 email@example.com
Kasper Roseeuw Poulsen +45 4442 4303 firstname.lastname@example.org
Frank Daniel Mersebach
Daniel Bohsen +45 4442 0604
+45 3079 6376 email@example.com
Lars Borup Jacobsen +45 3075 3479 firstname.lastname@example.org
Jannick Lindegaard (US) +1 609 786 4575 email@example.com
1. Natural History Museum website. Available at URL: http://www.nhm.ac.uk/nature-online/species-of-the-day/collections/collecting/trichopodiella-faurei/ . Last Accessed January, 2014
2. Novo Nordisk Data on file
3. Arendt-Nielsen L, et al. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23(1/2):37-43.
4. Birkebaek NH, et al. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care. 2008;31(9):e65.
5. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes. 2002;26(Suppl. 3):S18 - 24.
6. Brunton S. Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med. 2008;121:S35-S41
7. GFK Healthcare Diabetes Patient Market Study Roper Global Diabetes Programme 2006.
8. Novo Nordisk Data on file.
9. Novo Nordisk Data. Tested according to DS EN/ISO 11608-2:2012.
10. Gibney MA, et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for injectable therapy injections: Implications for needle length recommendations. Curr Med Res Opin. 2010;26:1519-1530.
11. Laurent A, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine. 2007;25:6423-6430.
12. Great Ormond Street Hospital website. Available at URL: http://www.gosh.nhs.uk/medical-conditions/medicines-information/giving-subcutaneous-injections/. Last Accessed January 2014.
13. Siegmund T, et al. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: “thin-wall” needles compared to “regular-wall” needles: an open-label study. Diabetes Technol Ther. 2009;11(8):523-528.
14. Novo Nordisk Data on file.